The $15 million raise provides near-term runway, but the sharp revenue decline and increasing R&D spend suggest ongoing dilution risk. Investors should closely monitor the Q3 2026 ELPIS II data readout as a critical value inflection point. The PRV monetization agreement may limit upside from regulatory incentives.
Price Chart
Executive Summary
Longeveron reported a 50% year-over-year revenue decline for 2025, driven by lower clinical trial and contract manufacturing demand, while net loss widened to $22.7 million. The company raised $15 million in a private placement, extending its cash runway into Q4 2026, and remains on track for pivotal Phase 2b HLHS trial results in Q3 2026. Despite positive clinical and regulatory developments, deteriorating financials dominate the near-term outlook.
Key Financial Metrics
Key Facts
- 2025 revenue was $1.2 million, down 50% from $2.4 million in 2024
- Net loss increased to $22.7 million in 2025 from $16.0 million in 2024
- Cash and cash equivalents dropped to $4.7 million from $19.2 million in 2024
- Raised $15 million in initial closing of a $30 million private placement led by Coastlands Capital and Janus Henderson
- Pivotal Phase 2b ELPIS II trial in HLHS expected to read out in Q3 2026, potentially supporting a BLA submission in 2027
- Investors in the private placement will receive 50% of proceeds from any future Pediatric Priority Review Voucher (PRV) sale related to HLHS
Financial Impact
Revenue down $1.2 million YoY, net loss up $6.7 million, cash burn of $14.5 million in 2025
Risk Factors
- High cash burn and reliance on future financings, increasing dilution risk
- Clinical trial failure risk in HLHS, which is central to the company's BLA and PRV strategy
- Limited revenue diversification and dependence on contract manufacturing and trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257647 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 8-K | $6.86 $2.49 | ▼ −63.70% | ▼ −64.52% | $2.57 (−62.61%) |
Jul 13, 2026 11w ago | 3 | $0.6223 $0.6022 | ▼ −3.23% | ▼ −1.93% | $2.57 (+312.18%) |
Jun 5, 2026 16w ago | 8-K | $0.7540 $0.7900 | ▲ +4.77% | ▲ +2.66% | $2.57 (+240.19%) |
May 20, 2026 19w ago | Press Release | $0.7210 $0.8150 | ▲ +13.04% | ▲ +11.44% | $2.57 (+255.76%) |
May 13, 2026 20w ago | 8-K | $0.7030 $0.7210 | ▲ +2.56% | ▲ +3.28% | $2.57 (+264.86%) |
May 8, 2026 20w ago | 8-K | $0.8380 $0.6760 | ▲ +19.33% | ▲ +19.25% | $2.57 (−206.09%) |
Apr 20, 2026 23w ago | EFFECT | $1.04 $0.9000 | ▲ +13.46% | ▲ +14.37% | $2.57 (−146.63%) |
Apr 10, 2026 24w ago | 8-K | $1.12 $1.04 | ▼ −7.14% | ▼ −10.44% | $2.57 (+129.02%) |
Apr 10, 2026 24w ago | S-1 | $1.12 $1.04 | ▲ +7.14% | ▲ +10.44% | $2.57 (−129.02%) |
Mar 17, 2026 28w ago | Press Release | $0.9760 $0.9730 | ▲ +0.31% | ▼ −0.41% | $2.57 (−162.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access